IDH1 and intrahepatic cholangiocarcinoma: Jiao et al evaluated 34 ICC registration groups and showed that the 3‐year survival rate in patients with IDH gene mutations was 33%, whereas the corresponding value in those with wild‐type IDH gene mutations was 81%.